comparemela.com
  1. Home
  2. Live Updates
  3. Siamak Daneshmand - Breaking News

Latest Breaking News On - Siamak daneshmand - Page 2 : comparemela.com

Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer

Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesObrian kenneyIndianj urolSiamak daneshmandJanssen pharmaceutical companies of johnsonExchange commissionCompanies of johnsonAmerican cancer societyKeck school of medicine universityJanssen research developmentJanssen biotech incNone of janssen research developmentNorris comprehensive cancer centerDrug administrationJanssen pharmaceutical companiesCancer treatment centers of america

Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase 2 SunRISe-1 study.

United statesIndianj urolObrian kenneySiamak daneshmandCancer treatment centers of americaJanssen biotech incJanssen pharmaceutical companies of johnsonWorld health organizationExchange commissionAmerican urological association annual meetingJanssen pharmaceutical companiesDrug administrationNorris comprehensive cancer centerCompanies of johnsonNone of janssen research developmentJanssen research development

Dr Daneshmand on the Investigation of Erdafitinib in NMIBC With FGFR2/3 Alterations

Siamak Daneshmand, MD, discusses the rationale for investigating erdafitinib in patients with recurrent, intermediate-risk non–muscle invasive bladder cancer harboring FGFR3 or FGFR2 alterations.

Siamak daneshmandUniversity of southern californiaClinical researchClinical scholarUrologic oncologySouthern californiaCancers symposiumNon muscle invasive bladder cancerGenitourinary cancersUrothelial cancerOnclive tv

AUA 2022: Case-Based Debate: In Patient with Pure T2 UC, PD-L1-high, GFR 60 do I need Neoadjuvant Therapy? Pro

AUA 2022: Case-Based Debate: In Patient with Pure T2 UC, PD-L1-high, GFR 60 do I need Neoadjuvant Therapy? Pro
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United statesSiamak daneshmandLos angelesShilpa guptaGenitourinary medical oncology at taussig cancer instituteDepartment of urologyAugusta university medical college of georgiaMeeting of the american urological associationAmerican urological associationKeck schoolSouthern californiaAssociate professorGenitourinary medical oncologyTaussig cancer instituteGenitourinary oncology programCleveland clinic

Kidney Function Not Worse After RC With Continent Diversion in Stage 3a CKD

A study investigated whether radical cystectomy with continent urinary diversion directly leads to kidney function loss.

Siamak daneshmandLos angelesRenal disease

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.